Lean Mass

Lean Mass

Lean mass — sometimes called fat-free mass — refers to all components of body mass that are not stored fat. It includes skeletal muscle, smooth muscle, organs, bone, connective tissue, and total body water. In clinical research it is most commonly measured by dual-energy X-ray absorptiometry (DXA or DEXA) scan, with magnetic resonance imaging used for higher-precision body composition substudies.

Lean mass matters during rapid weight loss because any caloric deficit produces some loss of both fat and lean tissue. The clinical concern is not weight loss in itself but the ratio of fat loss to lean mass loss. Healthy weight loss preserves as much lean mass as possible — both because lean mass (especially skeletal muscle) supports functional capacity, glucose disposal, and metabolic rate, and because lean mass loss in older adults contributes to sarcopenia, frailty, and increased fall risk.

In trials of GLP-1-class anti-obesity medications, approximately 25-40% of weight lost has historically come from lean mass, with the remainder coming from fat mass. This is broadly comparable to the ratio seen with dietary weight loss alone. Whether retatrutide’s triple-agonist mechanism — which adds glucagon receptor agonism (potentially altering protein turnover) and GIP receptor agonism (potentially affecting adipose tissue and bone) — changes this ratio is an active area of investigation. Phase 2 retatrutide DXA substudy data suggested a favorable fat-to-lean ratio, but Phase 3 data with larger samples will be more definitive.

For patients on any high-magnitude weight-loss therapy, clinical practice typically includes ensuring adequate protein intake (1.2-1.6 g/kg of ideal body weight per day), resistance exercise 2-3 times weekly, and periodic monitoring of functional capacity and grip strength.